OBJECTIVES: Orphan designation is a status assigned to a drug intended for use against rare condition. The drug must fulfil criteria for designation as an orphan medicine so that it can benefit from incentives like protection from competition once commercialized. In France, HAS (French National Authority for Health) reinforces requests for post-inscription studies, providing a better understanding of innovative drugs. This study aims to analyze their impact on reassessment focusing on orphan medicines.